Many patients hospitalized with severe heart failure are receiving potentially harmful treatment with intravenous fluids, a Yale-led study has found.

Younger adults with elevated systolic blood pressure have a higher risk for cardiovascular disease and coronary heart disease than those with normal blood pressure, according to a large long-term study of younger adults published online in the Journal of the American College of Cardiology. The risk was higher for women.

Medtronic announced the initiation of the Cryo4 Persistent AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) clinical trial.

Swedish Medical Center is the first facility in the Rocky Mountain Region to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF).

Cleveland Clinic and AliveCor, Inc. announced the online publication of study results from Cleveland Clinic’s iTransmit Study, "Evaluating the Efficacy and Feasibility of a Novel Wireless Recording System Using Smartphone in Monitoring Patients After Atrial Fibrillation Ablation Procedure.”

Medtronic announced CE (Conformité Européene) mark for the 26 and 29mm sizes of the CoreValve Evolut R System, a next-generation self-expanding valve for transcatheter aortic valve implantation (TAVI) providing the option to recapture and reposition the valve during procedures.

Ensuring that patients with peripheral arterial disease (PAD) get tested and treated with minimally invasive endovascular therapy saves legs and lives suggests a study in which amputation rates fell by nearly 80 percent after such a system was implemented.

A minimally invasive procedure to repair severe mitral valve regurgitation by clipping together the valve’s leaflets can improve function and quality of life and reduce the risk of hospitalization, research shows.

Case Western Reserve’s chemical compound aimed at restoring spinal cord function may have an additional purpose: stopping potentially fatal arrhythmias after heart attack.

United States hospitals began using a new medical device from Medtronic plc  called the In.Pact Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in the upper leg. PAD is a common cardiovascular condition that causes leg pain and increases the risk of heart attack and stroke.

Subscribe Now